Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells

Biomaterials

Volumn 34, Issue 26, 2013, Pages 6185-6193

  Yu, Bo ^a,b   Mao, Yicheng ^b   Yuan, Yuan ^b,c   Yue, Chaofang ^a,b   Wang, Xinmei ^b   Mo, Xiaokui ^b   Jarjoura, David ^b   Paulaitis, Michael E ^a,b   Lee, Robert J ^b   Byrd, John C ^b   Lee, L James ^a,b   Muthusamy, Natarajan ^b  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD37; Chronic lymphocytic leukemia; Dual targeting; Immunoliposomes

Indexed keywords

ADVERSE SIDE EFFECTS; ANTIBODY MICROARRAYS; CD37; CHRONIC LYMPHOCYTIC LEUKEMIAS; DUAL TARGETING; IMMUNOLIPOSOMES; PERSONALIZED NANOMEDICINE; TARGETED DRUG DELIVERY;

CELL CULTURE; CELL DEATH; DRUG DELIVERY; LIGANDS; MEDICAL NANOTECHNOLOGY; MONOCLONAL ANTIBODIES;

DISEASES;

CD37 ANTIGEN; IMMUNOLIPOSOME;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER THERAPY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LEUKEMIA CELL; MICROARRAY ANALYSIS; NANOMEDICINE; PRIORITY JOURNAL; RAJI CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, NEOPLASM; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPOSOMES; PROPYLENE GLYCOLS; SPHINGOSINE; TETRASPANINS;

EID: 84878654009     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.04.063     Document Type: Article

References (52)

1. Tam C.S., Keating M.J. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010, 7(9):521-532.
2. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. NEngl J Med 2005, 352(8):804-815.
3. Pleyer L., Egle A., Hartmann T.N., Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009, 6(7):405-418.
4. Jaglowski S.M., Byrd J.C. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010, 47(2):156-169.
5. Osterborg A., Fassas A.S., Anagnostopoulos A., Dyer M.J., Catovsky D., Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996, 93(1):151-153.
6. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001, 3(3):137-143.
7. Robak T., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. JClin Oncol 2010, 28(10):1756-1765.
8. Lin T.S., Moran M., Lucas M., Waymer S., Jefferson S., Fischer D.B., et al. Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematol Oncol Clin North Am 2004, 18(4):895-913.
9. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. JClin Oncol 2005, 23(18):4079-4088.
10. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. NEngl J Med 2008, 359(6):613-626.
11. Hertlein E., Triantafillou G., Sass E.J., Hessler J.D., Zhang X., Jarjoura D., et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010, 116(14):2554-2558.
12. Jaglowski S.M., Alinari L., Lapalombella R., Muthusamy N., Byrd J.C. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010 Nov 11, 116(19):3705-3714.
13. Zhao X., Lapalombella R., Joshi T., Cheney C., Gowda A., Hayden-Ledbetter M.S., et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007, 110(7):2569-2577.
14. Lapalombella R., Yeh Y.Y., Wang L., Ramanunni A., Rafiq S., Jha S., et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012, 21(5):694-708.
15. Robak T., Robak P., Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 2009, 10(12):1383-1390.
16. Moldenhauer G. Cd37. JBiol Regul Homeost Agents 2000, 14(4):281-283.
17. Schwartz-Albiez R., Dorken B., Hofmann W., Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. JImmunol 1988, 140(3):905-914.
18. Gupta P., Goldenberg D.M., Rossi E.A., Cardillo T.M., Byrd J.C., Muthusamy N., et al. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012, 119(16):3767-3778.
19. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012, 4(2).
20. Parren P.W., Burton D.R. Immunology. Two-in-one designer antibodies. Science 2009, 323(5921):1567-1568.
21. Alinari L., Yu B., Christian B.A., Yan F., Shin J., Lapalombella R., et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has invitro and invivo activity in mantle cell lymphoma. Blood 2011, 117(17):4530-4541.
22. Gupta P., Goldenberg D.M., Rossi E.A., Chang C.H. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010, 116(17):3258-3267.
23. Lapalombella R., Yu B., Triantafillou G., Liu Q., Butchar J.P., Lozanski G., et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008, 112(13):5180-5189.
24. Lapalombella R., Zhao X., Triantafillou G., Yu B., Jin Y., Lozanski G., et al. Anovel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008, 14(2):569-578.
25. Saul J.M., Annapragada A.V., Bellamkonda R.V. Adual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. JControl Release 2006, 114(3):277-287.
26. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. JControl Release 2011, 153(2):141-148.
27. Kluza E., Jacobs I., Hectors S.J., Mayo K.H., Griffioen A.W., Strijkers G.J., et al. Dual-targeting of alphavbeta3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium invivo. JControl Release 2012, 158(2):207-214.
28. Modery C.L., Ravikumar M., Wong T.L., Dzuricky M.J., Durongkaveroj N., Sen Gupta A. Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials 2011, 32(35):9504-9514.
29. Chen C.H., Liu D.Z., Fang H.W., Liang H.J., Yang T.S., Lin S.Y. Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer. Biosci Biotechnol Biochem 2008, 72(6):1586-1594.
30. Laginha K., Mumbengegwi D., Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005, 1711(1):25-32.
31. Sapra P., Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004, 10(7):2530-2537.
32. Chu T.W., Yang J., Kopecek J. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis. Biomaterials 2012, 33(29):7174-7181.
33. Yu B., Mao Y., Bai L.Y., Herman S.E., Wang X., Ramanunni A., et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 2013, 121(1):136-147.
34. Chiu G.N., Edwards L.A., Kapanen A.I., Malinen M.M., Dragowska W.H., Warburton C., et al. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther 2007, 6(3):844-855.
35. Popov Jesse, Kapanen A.I., Turner Christopher, Ng Rebecca, Tucker Catherine, Chiu Gigi, et al. Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and invivo activity. Nanomedicine 2011, 6(9):1575-1591.
36. Iden D.L., Allen T.M. Invitro and invivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001, 1513(2):207-216.
37. Allen T.M., Sapra P., Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 2002, 7(3):889-894.
38. Yicheng Mao J.W., Wu Yun, Chen Ching-Shih, Phelps Mitch A., Lee Robert J., Lee L.James, et al. Anovel liposome formulation of FTY720. Nanomedicine 2013.
39. Loisel S., Andre P.A., Golay J., Buchegger F., Kadouche J., Cerutti M., et al. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Mol Cancer 2011, 10:42.
40. Chao M.P., Alizadeh A.A., Tang C., Myklebust J.H., Varghese B., Gill S., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142(5):699-713.
41. Heider K.H., Kiefer K., Zenz T., Volden M., Stilgenbauer S., Ostermann E., et al. Anovel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011, 118(15):4159-4168.
42. Krause G., Patz M., Isaeva P., Wigger M., Baki I., Vondey V., et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012, 26(3):546-549.
43. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2(10):750-763.
44. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002, 62(24):7190-7194.
45. Belov L., Huang P., Barber N., Mulligan S.P., Christopherson R.I. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003, 3(11):2147-2154.
46. Belov L., Mulligan S.P., Barber N., Woolfson A., Scott M., Stoner K., et al. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 2006, 135(2):184-197.
47. Kato K., Toda M., Iwata H. Antibody arrays for quantitative immunophenotyping. Biomaterials 2007, 28(6):1289-1297.
48. Grillo-Lopez A.J., White C.A., Dallaire B.K., Varns C.L., Shen C.D., Wei A., et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000, 1(1):1-9.
49. Liu Q., Alinari L., Chen C.S., Yan F., Dalton J.T., Lapalombella R., et al. FTY720 shows promising invitro and invivo preclinical activity by downmodulating cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010, 16(12):3182-3192.
50. Liu Q., Zhao X., Frissora F., Ma Y., Santhanam R., Jarjoura D., et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111(1):275-284.
51. Kontermann R.E. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006, 8(1):39-45.
52. White C.A., Weaver R.L., Grillo-Lopez A.J. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001, 52:125-145.